AI assistant
INSMED Inc — Director's Dealing 2024
May 30, 2024
30150_dirs_2024-05-30_9a1a1ed9-066f-4a7e-bfcf-d2ba7793d643.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INSMED Inc (INSM)
CIK: 0001104506
Period of Report: 2024-05-28
Reporting Person: Bonstein Sara (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-28 | Common Stock | M | 3454 | $28.88 | Acquired | 120935 | Direct |
| 2024-05-29 | Common Stock | M | 76731 | $28.88 | Acquired | 197666 | Direct |
| 2024-05-28 | Common Stock | M | 3454 | $24.70 | Acquired | 201120 | Direct |
| 2024-05-29 | Common Stock | M | 27074 | $24.70 | Acquired | 228194 | Direct |
| 2024-05-28 | Common Stock | M | 3454 | $34.03 | Acquired | 231648 | Direct |
| 2024-05-29 | Common Stock | M | 25046 | $34.03 | Acquired | 256694 | Direct |
| 2024-05-28 | Common Stock | M | 3454 | $26.46 | Acquired | 260148 | Direct |
| 2024-05-29 | Common Stock | M | 39446 | $26.46 | Acquired | 299594 | Direct |
| 2024-05-28 | Common Stock | M | 3454 | $26.43 | Acquired | 303048 | Direct |
| 2024-05-29 | Common Stock | M | 20111 | $26.43 | Acquired | 323159 | Direct |
| 2024-05-28 | Common Stock | M | 3454 | $17.07 | Acquired | 326613 | Direct |
| 2024-05-29 | Common Stock | M | 32156 | $17.07 | Acquired | 358769 | Direct |
| 2024-05-28 | Common Stock | S | 20724 | $50.01 | Disposed | 338045 | Direct |
| 2024-05-29 | Common Stock | S | 220564 | $50 | Disposed | 117481 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-28 | Stock Option (right to buy) | $28.88 | M | 3454 | Disposed | 2030-02-03 | Common Stock (3454) | Direct |
| 2024-05-29 | Stock Option (right to buy) | $28.88 | M | 76731 | Disposed | 2030-02-03 | Common Stock (76731) | Direct |
| 2024-05-28 | Stock Option (right to buy) | $24.70 | M | 3454 | Disposed | 2030-05-12 | Common Stock (3454) | Direct |
| 2024-05-29 | Stock Option (right to buy) | $24.70 | M | 27074 | Disposed | 2030-05-12 | Common Stock (27074) | Direct |
| 2024-05-28 | Stock Option (right to buy) | $34.03 | M | 3454 | Disposed | 2031-01-07 | Common Stock (3454) | Direct |
| 2024-05-29 | Stock Option (right to buy) | $34.03 | M | 25046 | Disposed | 2031-01-07 | Common Stock (25046) | Direct |
| 2024-05-28 | Stock Option (right to buy) | $26.46 | M | 3454 | Disposed | 2031-05-12 | Common Stock (3454) | Direct |
| 2024-05-29 | Stock Option (right to buy) | $26.46 | M | 39446 | Disposed | 2031-05-12 | Common Stock (39446) | Direct |
| 2024-05-28 | Stock Option (right to buy) | $26.43 | M | 3454 | Disposed | 2032-01-06 | Common Stock (3454) | Direct |
| 2024-05-29 | Stock Option (right to buy) | $26.43 | M | 20111 | Disposed | 2032-01-06 | Common Stock (20111) | Direct |
| 2024-05-28 | Stock Option (right to buy) | $17.07 | M | 3454 | Disposed | 2032-05-11 | Common Stock (3454) | Direct |
| 2024-05-29 | Stock Option (right to buy) | $17.07 | M | 32156 | Disposed | 2032-05-11 | Common Stock (32156) | Direct |
Footnotes
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 20,724 shares sold at prices ranging from $50.00 to $50.07 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 220,564 shares sold at prices ranging from $50.00 to $50.08 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
F5: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date.